Homepage
PR Newswire
Portal
Search
Member List
Help
Hello There, Guest!
Login
Register
Login
Username:
Password:
Lost Password?
Remember me
ValueBuddies.com : Value Investing Forum - Singapore, Hong Kong, U.S.
PR Newswire
Pages (734):
« Previous
1
…
365
366
367
368
369
…
734
Next »
Jump to page:
Date & Time
Title
Mon, 03 Jun 2024 08:00:00 +0800
Darren Bishop Joins TradeFlow Capital Management as Head of Strategic Partnerships (UK/Europe)
Mon, 03 Jun 2024 08:00:00 +0800
DB HiTek Advances Global Shutter and SPAD
Mon, 03 Jun 2024 08:00:00 +0800
MTN Japan Deploys FutureDial NDSE™ Solution for Automating the Data-Clearing and Refurbishing of Used Networking Equipment for Resale
Mon, 03 Jun 2024 07:11:00 +0800
Kerry Logistics Network Named Global Logistics Company of Excellence by Hong Kong Economic Journal Corporate Brand Awards of Excellence 2024
Sun, 02 Jun 2024 23:32:00 +0800
Rokid AR Lite Crowdfunding Surpasses $600,000 with One Day Left for Early Bird Price of $479
Sun, 02 Jun 2024 23:20:00 +0800
LENNY KRAVITZ ROCKS OUT AT THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®
Sun, 02 Jun 2024 22:25:00 +0800
ASRock Rack Launches New Servers Supporting the NVIDIA Blackwell Architecture at COMPUTEX 2024
Sun, 02 Jun 2024 13:19:00 +0800
Innovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
Sun, 02 Jun 2024 08:25:00 +0800
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
Sun, 02 Jun 2024 08:24:00 +0800
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
Sun, 02 Jun 2024 08:00:00 +0800
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
Sun, 02 Jun 2024 08:00:00 +0800
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
Sun, 02 Jun 2024 08:00:00 +0800
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
Sun, 02 Jun 2024 07:13:00 +0800
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting
Sun, 02 Jun 2024 03:00:00 +0800
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting
Sat, 01 Jun 2024 23:40:00 +0800
Z Grills Announces Unprecedented "Buy 1, Get 10 Grills" Promotion, Unlocking a Lifetime of Easier Grilling!
Sat, 01 Jun 2024 23:00:00 +0800
ICECO Launches APL35 on Indiegogo - The World's Lightest Aluminum Dual-Zone Freezer
Sat, 01 Jun 2024 20:00:00 +0800
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
Sat, 01 Jun 2024 20:00:00 +0800
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
Sat, 01 Jun 2024 19:10:00 +0800
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
Pages (734):
« Previous
1
…
365
366
367
368
369
…
734
Next »
Jump to page: